Krystal Biotech, Inc. Quarterly Debt-to-equity in % from Q2 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Krystal Biotech, Inc. quarterly Debt-to-equity history and growth rate from Q2 2018 to Q3 2024.
  • Krystal Biotech, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 8.15 %, a 37% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 8.15 +2.2 +37% Sep 30, 2024
Q2 2024 6.52 -0.05 -0.76% Jun 30, 2024
Q1 2024 5.33 -2.07 -28% Mar 31, 2024
Q4 2023 5.5 -2.9 -34.5% Dec 31, 2023
Q3 2023 5.94 -2.03 -25.5% Sep 30, 2023
Q2 2023 6.57 -2.24 -25.4% Jun 30, 2023
Q1 2023 7.4 -1.18 -13.8% Mar 31, 2023
Q4 2022 8.4 +2.29 +37.5% Dec 31, 2022
Q3 2022 7.97 +1.59 +24.9% Sep 30, 2022
Q2 2022 8.82 +4.25 +93.1% Jun 30, 2022
Q1 2022 8.58 +4.88 +132% Mar 31, 2022
Q4 2021 6.1 +2.14 +54% Dec 31, 2021
Q3 2021 6.39 +3.32 +108% Sep 30, 2021
Q2 2021 4.57 +1.53 +50.4% Jun 30, 2021
Q1 2021 3.7 +0.43 +13.2% Mar 31, 2021
Q4 2020 3.97 +0.38 +10.6% Dec 31, 2020
Q3 2020 3.07 -0.52 -14.5% Sep 30, 2020
Q2 2020 3.04 -0.79 -20.6% Jun 30, 2020
Q1 2020 3.26 -0.49 -13% Mar 31, 2020
Q4 2019 3.59 +1.16 +47.8% Dec 31, 2019
Q3 2019 3.59 +1.53 +74.1% Sep 30, 2019
Q2 2019 3.83 +1.58 +70.3% Jun 30, 2019
Q1 2019 3.76 Mar 31, 2019
Q4 2018 2.43 Dec 31, 2018
Q3 2018 2.06 Sep 30, 2018
Q2 2018 2.25 Jun 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.